Aligos' HBV Drug ALG-170675 Enters Phase 1 Trials in China
Event summary
- Aligos Therapeutics' ALG-170675, an antisense oligonucleotide for chronic HBV treatment, has dosed its first participant in a Phase 1 study conducted by partner Amoytop in China.
- The trial will evaluate single and multiple ascending doses, with plans to include chronic HBV patients in Q4 2026.
- ALG-170675 is designed for both HBsAg RNA inhibition and immuno-activation, potentially offering improved functional cure rates.
- Amoytop holds rights to the drug candidate in Greater China.
The big picture
Aligos' Phase 1 trial initiation for ALG-170675 underscores its strategic focus on developing next-generation therapies for chronic HBV, a disease with significant unmet medical needs. The collaboration with Amoytop highlights the importance of regional partnerships in accelerating drug development and addressing global health challenges. Success in this trial could position Aligos as a key player in the HBV treatment landscape.
What we're watching
- Clinical Progress
- The pace at which ALG-170675 advances through Phase 1 and into chronic HBV patient trials will indicate its development momentum.
- Combination Therapy Potential
- Whether ALG-170675 can be effectively combined with Amoytop’s PEGBING® or Aligos’ pevifoscorvir sodium to enhance functional cure rates for chronic HBV.
- Regulatory Pathway
- How the Chinese regulatory environment will impact the approval and commercialization timeline for ALG-170675 in Greater China.
Related topics